9 completed, 3 unknown. 12 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Unknown 3 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow epoetin beta: new trials by email Literature Review of epoetin beta trials Research Report on epoetin beta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis EPO, Normal saline - Premature Infant | Phase 2 | Completed | Zhengzhou University | 1285 | 2014-01-01 | 2019-04-19 |
| Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans Erythropoietin (Epoetin beta), Placebo - Healthy | Phase 1 / Phase 2 | Unknown | University of Zurich | 32 | 2013-02-01 | 2013-06-28 |
| Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. Lenalidomide, Epoetin beta - Myelodysplastic Syndromes | Phase 2 | Completed | Groupe Francophone des Myelodysplasies | 132 | 2010-07-01 | 2016-11-08 |
| Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS) Epoetin beta (NeoRecormon) - Myelodysplastic Syndromes | Phase 2 | Completed | Groupe Francophone des Myelodysplasies | 50 | 2010-06-01 | 2015-04-29 |
| The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis Erythropoietin - Multiple Sclerosis (Primary or Secondary Progressive Phase). | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 56 | 2009-11-01 | 2011-08-08 |
| Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA) Azacitidine, Epoetin beta - Myelodysplastic Syndromes | Phase 2 | Completed | Groupe Francophone des Myelodysplasies | 98 | 2009-02-01 | 2014-03-19 |
| Randomized Trial of Erythropoietin During Cerebral Malaria Placebo, Erythropoietin - Cerebral Malaria | Phase 2 / Phase 3 | Unknown | Claude Bernard University | 120 | 2007-10-01 | 2008-06-13 |
| A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. Mycophenolate mofetil, Prednisone, Erythropoietin Beta - Myelodysplastic Syndromes | Phase 2 | Completed | Hoffmann-La Roche | 10 | 2007-08-01 | 2016-07-25 |
| Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery Erythropoietin-Beta, Normal Saline - Kidney Failure, Acute | Phase 2 / Phase 3 | Completed | Seoul National University Bundang Hospital | 71 | 2006-09-01 | 2009-06-16 |
| Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB epoetin beta, placebo - Myocardial Ischemia | Phase 2 | Completed | University Hospital, Grenoble | 50 | 2006-01-01 | 2009-12-07 |
| Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors epoetin beta, quality-of-life assessment - Anemia, Fatigue | Phase 2 | Completed | Centre Hospital Regional Universitaire de Limoges | 40 | 2005-11-01 | 2011-05-16 |
| A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy Epoetin Beta - Anemia | Phase 2 | Completed | Hoffmann-La Roche | 200 | 2004-02-29 | 2018-08-24 |
Myelodysplastic Syndromes (4) · Anemia (2) · Acute Kidney Injury (1) · Anemia, Refractory, with Excess of Blasts (1) · Enterocolitis, Necrotizing (1) · Fatigue (1) · Malaria (1) · Malaria, Cerebral (1) · Motor Activity (1) · Multiple Sclerosis (1) · Multiple Sclerosis, Chronic Progressive (1) · Myocardial Ischemia (1) · Premature Birth (1)
Groupe Francophone des Myelodysplasies (3) · Hoffmann-La Roche (2) · Centre Hospital Regional Universitaire de Limoges (1) · Claude Bernard University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Seoul National University Bundang Hospital (1) · University Hospital, Grenoble (1) · University of Zurich (1) · Zhengzhou University (1)
France (5) · China (1) · Denmark (1) · Italy (1) · Mali (1) · Monaco (1) · South Korea (1) · Spain (1) · Switzerland (1)
Changlian Zhu, PhD (1) · Claude Gardin, MD (1) · Jean-Luc Labourey (1) · Karen Schreiber, MD., Ph.d. (1) · Ki Young, Na, MD PhD (1) · Marco Maggiorini, Prof MD (1) · Per S Soerensen, MD., Prof (1) · Simone Boehrer, MD (1)
PMID 19630971, PMID 26626993, PMID 27229713, PMID 32771013, PMID 33076939, PMID 39301879